Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, People's Republic of China.
Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, Jiangsu, People's Republic of China.
Clin Pharmacol Drug Dev. 2023 Jan;12(1):70-76. doi: 10.1002/cpdd.1157. Epub 2022 Sep 4.
To assess the bioequivalence of a generic safinamide tablet (test) vs a brand-name safinamide tablet (reference) and effects of food on the pharmacokinetics of safinamide in healthy Chinese subjects, a single-center, single-dose, randomized, open-label, 2-preparation, 2-period study with a 15-day washout period was undertaken. A total of 56 healthy subjects were recruited in this study (fasting, n = 28; fed, n = 28). A single dose of a 100-mg test or reference safinamide tablet was administered to each subject in a randomized sequence. Blood samples were obtained at 5 minutes before drug administration and during the 120 hours after dosing. The safinamide concentration in plasma was determined by high-performance liquid chromatography-tandem mass spectrometry. Pharmacokinetic parameters were analyzed with noncompartmental methods. Safety was also monitored. The major pharmacokinetic parameters including maximum plasma drug concentration, area under plasma concentration-time curve (AUC) from zero to time t (AUC ), and AUC from time 0 to infinity (AUC ) were similar between the test and reference tablets under fasting and fed conditions. The 90% CIs of the test/reference ratios of log-transformed maximum plasma drug concentration, AUC from zero to time t, and AUC from time 0 to infinity all fell within the equivalence interval (80.0%-125%) whether under fasting condition or fed condition. In conclusion, the 2 formulations of safinamide tablets were bioequivalent and well tolerated under both fasting and fed conditions in healthy Chinese volunteers. High-fat food delayed the absorption of safinamide but did not affect the final bioavailability.
为评估仿制药沙非酰胺片(试验)与原研药沙非酰胺片(参比制剂)的生物等效性,以及食物对健康中国受试者沙非酰胺药代动力学的影响,开展了一项单中心、单剂量、随机、开放标签、2 制剂、2 周期、15 天洗脱期的研究。该研究共纳入 56 例健康受试者(禁食,n=28;进食,n=28)。每位受试者按随机顺序接受单剂量 100 mg 试验或参比制剂沙非酰胺片。于给药前 5 分钟及给药后 120 小时采集血样。采用高效液相色谱-串联质谱法测定血浆中沙非酰胺的浓度。采用非房室模型法分析药代动力学参数。同时监测安全性。空腹和进食条件下,试验制剂和参比制剂的主要药代动力学参数(包括最大血药浓度、从 0 到时间 t 的血浆浓度-时间曲线下面积(AUC )、从 0 到无穷大的 AUC )相似。对数转换后的最大血药浓度、从 0 到时间 t 的 AUC 、从 0 到无穷大的 AUC ,试验/参比比值的 90%置信区间(CI)均在 80.0%-125%等效区间内,无论空腹还是进食条件。结论:沙非酰胺片两种制剂在健康中国志愿者中空腹和进食条件下均具有生物等效性,且均具有良好的耐受性。高脂肪食物延迟了沙非酰胺的吸收,但不影响最终的生物利用度。